Abstract
Dysfunction of monoacylglycerol lipase (MAGL) is associated with several psychopathological disorders, including drug addiction and neurodegenerative diseases. Herein we design, synthesize, and evaluate several irreversible fluorine-containing MAGL inhibitors for positron emission tomography (PET) ligand development. Compound 6 (identified from a therapeutic agent) was advanced for 18F-labeling via a novel spirocyclic iodonium ylide (SCIDY) strategy, which demonstrated high brain permeability and excellent specific binding. This work supports further development of novel 18F-labeled MAGL PET probes.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Binding Sites
-
Blood-Brain Barrier / drug effects
-
Blood-Brain Barrier / metabolism
-
Brain / diagnostic imaging
-
Contrast Media / chemical synthesis*
-
Contrast Media / metabolism
-
Drug Design*
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / metabolism
-
Enzyme Inhibitors / pharmacology
-
Fluorine Radioisotopes / chemistry
-
Isotope Labeling
-
Molecular Docking Simulation
-
Monoacylglycerol Lipases / antagonists & inhibitors*
-
Monoacylglycerol Lipases / metabolism
-
Positron-Emission Tomography
-
Rats
-
Spiro Compounds / chemistry
-
Tissue Distribution
Substances
-
Contrast Media
-
Enzyme Inhibitors
-
Fluorine Radioisotopes
-
Spiro Compounds
-
Monoacylglycerol Lipases
-
Fluorine-18